Literature DB >> 9616372

Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.

R M Gorczynski1, Z Chen, H Zeng, L Gorczynski, E Terzioglu.   

Abstract

Irradiated (800 rads) AKR mice received intravenous (i.v.) reconstitution with a mixture of B10.BR T-depleted bone marrow cells and spleen cells. Only in groups of mice treated additionally with i.v. cyclophosphamide (Cy; 150 mg/kg), 24 hr before transplantation, was long-term (> 60% at 50 days) survival seen. In mice receiving only irradiation all animals died by 30 days post-transplantation. Histological changes consistent with graft-versus-host disease (GVHD) were seen in the liver of reconstituted mice at 30 days, along with an organ-specific increase in V beta 3 T-cell receptor-positive (TCR+) cells. No such increase in V beta 3 TCR+ cells was seen in the spleen from the same mice. These data are consistent with a tissue antigen-driven expansion of V beta 3 TCR+ cells associated with GVHD in the liver in this model. When we analysed cytokine production in vitro from CD3+ cells restimulated with 'host' (AKR) antigen-presenting cells (APC), we found a transition in cytokine production from preferential synthesis of type-1 cytokines [interleukin-2 (IL-2) and interferon-gamma (IFN-gamma)] at early times (day 15) post-reconstitution to increased production of type-2 cytokines [IL-4, transforming growth factor-beta (TGF-beta) and IL-10] at later times (day 30) post-reconstitution in Cy-treated recipients. Animals not receiving Cy did not show this 'switch' in cytokine production at later time points. We have observed a similar polarization in cytokine production, along with increased graft survival, in recipients of vascularized and non-vascularized allografts after portal venous (p.v.), but not i.v., pretransplant donor-specific immunization. We next studied AKR mice receiving 800 rads and subsequently reconstituted with B10.BR stem cells via the p.v. route. Again these mice showed prolonged survival (> 50% at 50 days), with polarization to IL-4, IL-10 and TGF-beta on restimulation of CD3+ cells in vitro at 30 days post-transplant and increased V beta 3 TCR+ cells in the liver. Infusion of anti-IL-12 monoclonal antibodies into irradiated mice receiving i.v. cell reconstitution produced a similar pattern of changes to those seen after p.v. reconstitution, while a combination of anti-IL-10 and anti-TGF-beta monoclonal antibodies reversed the changes seen after p.v. reconstitution. These data are consistent with an important role for differential cytokine production in the regulation of GVHD following allogeneic bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616372      PMCID: PMC1364182          DOI: 10.1046/j.1365-2567.1998.00403.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Specific manipulation in vivo of immunity to skin grafts bearing multiple minor histocompatibility differences.

Authors:  R M Gorczynski; W Holmes
Journal:  Immunol Lett       Date:  1991-02       Impact factor: 3.685

2.  A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1, and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion.

Authors:  R M Gorczynski; D Wojcik
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

Review 3.  Bone marrow transplantation.

Authors:  J O Armitage
Journal:  N Engl J Med       Date:  1994-03-24       Impact factor: 91.245

4.  Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination.

Authors:  M Cavazzana-Calvo; J L Stephan; S Sarnacki; S Chevret; C Fromont; C de Coene; F Le Deist; D Guy-Grand; A Fischer
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

5.  IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.

Authors:  M Sykes; V S Abraham; M W Harty; D A Pearson
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

6.  IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease.

Authors:  C S Via; V Rus; M K Gately; F D Finkelman
Journal:  J Immunol       Date:  1994-11-01       Impact factor: 5.422

Review 7.  Clinical application of cytokines for cancer treatment.

Authors:  F Takaku
Journal:  Oncology       Date:  1994 Mar-Apr       Impact factor: 2.935

8.  Adoptive transfer of unresponsiveness to allogeneic skin grafts with hepatic gamma delta + T cells.

Authors:  R M Gorczynski
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

9.  Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones.

Authors:  D van der Harst; E Goulmy; J H Falkenburg; Y M Kooij-Winkelaar; S A van Luxemburg-Heijs; H M Goselink; A Brand
Journal:  Blood       Date:  1994-02-15       Impact factor: 22.113

10.  Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.

Authors:  M Sykes; M W Harty; G L Szot; D A Pearson
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

View more
  1 in total

Review 1.  Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction.

Authors:  H J Deeg
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.